Net clinical benefit (95% CIs) per 100 person-years with warfarin, by CHA2DS2-VASC scores and sex
| Total stroke events | Net clinical benefit | ||
|---|---|---|---|
| Ischaemic stroke | Haemorrhagic stroke | ||
| CHA2DS2-VASc scores | |||
| Overall population | |||
| 0 | 28 | 8 | −0.3 (−0.8 to 0.1) |
| 1 | 153 | 54 | 0.1 (−0.2 to 0.4) |
| 2 | 453 | 95 | 0.2 (−0.1 to 0.6) |
| 3 | 1013 | 165 | 1.5 (1.2 to 1.8) |
| 4 | 1673 | 237 | 2.2 (1.8 to 2.6) |
| 5 | 1416 | 180 | 3.2 (2.6 to 3.8) |
| 6 | 1360 | 104 | 7.7 (6.7 to 8.8) |
| 7 | 692 | 45 | 7.2 (5.2 to 9.1) |
| 8 | 185 | 18 | 12.8 (8.9 to 16.9) |
| 9 | 32 | 0 | 16.8 (1.8 to 31.5) |
| 0–9 | 7005 | 906 | 1.9 (1.8 to 2.1) |
| Men | |||
| 0 | 28 | 8 | −0.3 (−0.8 to 0.1) |
| 1 | 137 | 48 | 0.1 (−0.2 to 0.4) |
| 2 | 381 | 79 | 0.5 (0.1 to 0.9) |
| 3 | 656 | 103 | 1.5 (1.1 to 1.9) |
| 4 | 608 | 93 | 2.0 (1.3 to 2.7) |
| 5 | 613 | 88 | 3.9 (2.6 to 4.9) |
| 6 | 363 | 26 | 7.1 (5.2 to 9.1) |
| 7 | 156 | 15 | 8.6 (4.7 to 13.0) |
| 8 | 21 | 3 | 15.9 (7.0 to 25.7) |
| 0–8 | 2963 | 463 | 1.2 (1.0 to 1.4) |
| Women | |||
| 1 | 16 | 6 | 0.3 (−0.4 to 0.8) |
| 2 | 72 | 16 | −0.1 (−0.6 to 0.3) |
| 3 | 357 | 62 | 1.5 (1.1 to 1.9) |
| 4 | 1065 | 144 | 2.4 (2.0 to 2.8) |
| 5 | 803 | 92 | 3.1 (2.3 to 3.8) |
| 6 | 997 | 78 | 8.0 (6.6 to 9.3) |
| 7 | 536 | 30 | 6.8 (4.4 to 9.1) |
| 8 | 164 | 15 | 12.4 (7.9 to 17.3) |
| 9 | 32 | 0 | 16.8 (3.1 to 30.5) |
| 1–9 | 4042 | 443 | 2.7 (2.4 to 3.0) |